Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655064 (Buffer Solution for Injection) in Healthy Chinese and Japanese Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)

Trial Profile

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655064 (Buffer Solution for Injection) in Healthy Chinese and Japanese Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2015

At a glance

  • Drugs BI 655064 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 19 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 07 Mar 2014 The number of treatment arms changed from 4 to 8 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top